CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 25, 2004
Result type: Reports
Project Number: SR0023-000
Product Line: Reimbursement Review

Generic Name: Voriconazole

Brand Name: VFEND

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Aspergillosis, Invasive

Indications: Aspergillosis, Invasive

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: April 14, 2005

Recommendation Type: List with clinical criteria and/or conditions